search
Back to results

The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study

Primary Purpose

Schizophrenia

Status
Completed
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
Sodium Nitroprusside infusion
Placebo
Sponsored by
King's College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Schizophrenia focused on measuring Nitric Oxide, Sodium Nitroprusside, Spatial Working Memory, Psychosis, Schizophrenia

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients with a diagnosis of schizophrenia or schizoaffective disorder, currently experiencing an exacerbation of symptoms (a score > 20 for PANSS-Positive subscale), currently taking antipsychotics and who have given informed consent to participate.

Exclusion Criteria:

History of hypertension or current resting systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg. Relevant medical illness (renal, hepatic, cardiac), prior history of intolerance to sodium nitroprusside, presence of a seizure disorder, any change in psychotropic medication in previous 6 weeks, diagnosis of substance abuse, pregnancy (as determined by urine test) or breastfeeding.

Sites / Locations

  • Clinical Research Facility, King's College Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Glucose infusion

Sodium Nitroprusside infusion

Arm Description

Placebo infusion of sterile 5% glucose - 500ml infused over 4 hours.

Sodium nitroprusside dissolved in 5% glucose solution. Infused at 0.5mcg/kg/min for 4 hours.

Outcomes

Primary Outcome Measures

Spatial Working Memory
performance on Cambridge Neuropsychological Test Automated Battery spatial working memory task

Secondary Outcome Measures

Positive and Negative Syndrome Scale (PANSS)
Symptoms rated on PANSS
Brief Psychiatric Rating Scale (BPRS)
Symptoms rated on BPRS
Quick Inventory of Depressive Symptomatology (QIDS)
Symptoms rated on QIDS
Hypomania Checklist (HCL-32)
Rating of symptoms on HCL-32
Blood pressure
Measurement of blood pressure.
Heart rate
Heart rate change from baseline
Respiratory rate
change in respiratory rate from baseline.

Full Information

First Posted
June 25, 2014
Last Updated
March 8, 2016
Sponsor
King's College London
search

1. Study Identification

Unique Protocol Identification Number
NCT02176044
Brief Title
The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study
Official Title
The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
August 2014 (undefined)
Primary Completion Date
February 2016 (Actual)
Study Completion Date
February 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
King's College London

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Spatial working memory (ability to remember where objects are in space) is impaired in patients with schizophrenia. It is thought that this impairment occurs due to problems with the chemical messenger (neurotransmitter), glutamate, and the N-methyl-D-aspartate (NMDA) glutamate receptor, particularly in the hippocampal brain region. NMDA receptor activation leads to increases in the release of the second messenger Nitric Oxide. Impaired NMDA receptor function would therefore be predicted to lead to reductions in Nitric Oxide production. Recent work suggests that a drug, sodium nitroprusside, which releases nitric oxide, enhances some aspects of cognition in schizophrenia (specifically related to negative symptoms). In this study, the investigators will test the hypothesis that sodium nitroprusside improves spatial working memory in patients with schizophrenia. 15 patients will receive sodium nitroprusside, and 15 will receive a nonactive compound (placebo). Their performance on a spatial working memory task will be tested before and after administration of sodium nitroprusside or placebo.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
Keywords
Nitric Oxide, Sodium Nitroprusside, Spatial Working Memory, Psychosis, Schizophrenia

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
21 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Glucose infusion
Arm Type
Placebo Comparator
Arm Description
Placebo infusion of sterile 5% glucose - 500ml infused over 4 hours.
Arm Title
Sodium Nitroprusside infusion
Arm Type
Active Comparator
Arm Description
Sodium nitroprusside dissolved in 5% glucose solution. Infused at 0.5mcg/kg/min for 4 hours.
Intervention Type
Drug
Intervention Name(s)
Sodium Nitroprusside infusion
Intervention Type
Other
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Spatial Working Memory
Description
performance on Cambridge Neuropsychological Test Automated Battery spatial working memory task
Time Frame
4 hours post-infusion
Secondary Outcome Measure Information:
Title
Positive and Negative Syndrome Scale (PANSS)
Description
Symptoms rated on PANSS
Time Frame
4 hours post-infusion
Title
Brief Psychiatric Rating Scale (BPRS)
Description
Symptoms rated on BPRS
Time Frame
4 hours post-infusion
Title
Quick Inventory of Depressive Symptomatology (QIDS)
Description
Symptoms rated on QIDS
Time Frame
4 hours post-infusion
Title
Hypomania Checklist (HCL-32)
Description
Rating of symptoms on HCL-32
Time Frame
4 hours post-infusion
Title
Blood pressure
Description
Measurement of blood pressure.
Time Frame
4 hours post-infusion
Title
Heart rate
Description
Heart rate change from baseline
Time Frame
4 hours post-infusion
Title
Respiratory rate
Description
change in respiratory rate from baseline.
Time Frame
4 hours post-infusion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with a diagnosis of schizophrenia or schizoaffective disorder, currently experiencing an exacerbation of symptoms (a score > 20 for PANSS-Positive subscale), currently taking antipsychotics and who have given informed consent to participate. Exclusion Criteria: History of hypertension or current resting systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg. Relevant medical illness (renal, hepatic, cardiac), prior history of intolerance to sodium nitroprusside, presence of a seizure disorder, any change in psychotropic medication in previous 6 weeks, diagnosis of substance abuse, pregnancy (as determined by urine test) or breastfeeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James Stone, MBBS PhD
Organizational Affiliation
King's College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Research Facility, King's College Hospital
City
London
ZIP/Postal Code
SE5
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
27655012
Citation
Stone JM, Morrison PD, Koychev I, Gao F, Reilly TJ, Kolanko M, Mohammadinasab A, Kapur S, McGuire PK. The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Psychol Med. 2016 Dec;46(16):3443-3450. doi: 10.1017/S0033291716002245. Epub 2016 Sep 22.
Results Reference
derived

Learn more about this trial

The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study

We'll reach out to this number within 24 hrs